A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)

Tong et al., NCT04483960, ASCOT, NCT04483960, Dec 2025
Estimated 2,200 patient remdesivir late treatment RCT with results not reported over 10 months after estimated completion.
Gérard, Zhou, Wu, Kamo, Choi, Kim show increased risk of acute kidney injury, Leo, Briciu, Muntean, Petrov, Arch show increased risk of liver injury, Negru, Cheng, Mohammed, Kwok, Zhu show increased risk of cardiac disorders, and Kwok, Merches, Akinci, Tang, Bagheri show increased risk of mitochondrial toxicity with remdesivir.
Study covers remdesivir and paxlovid.
Tong et al., 31 Dec 2025, Randomized Controlled Trial, Australia, trial NCT04483960 (history) (ASCOT).
Late treatment
is less effective